Solid oral dosage forms of eslicarbazepine
US10918604B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 16, 2016 |
| Grant date | Feb 16, 2021 |
| Priority date | — |
| Expiry date | Apr 29, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/205
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to high drug load pharmaceutical compositions comprising Eslicarbazepine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof. The present invention also relates to a process for preparing high drug load solid oral pharmaceutical composition comprising Eslicarbazepine acetate and at least one pharmaceutically acceptable excipient. The prior art highlights various technical challenges for formulation development of Eslicarbazepine acetate at lab as well as at industrial scale and offer restrictive and complex approach for resolution of technical challenges. Compositions of Eslicarbazepine acetate prepared as per present invention, wherein disintegrant and/or binder is present in either intra-granular part or in extra-granular part of the composition exhibited desirable technical attributes like comparable dissolution and bioequivalence against reference listed drug.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.